ABSTRACT
AIM To observe the effects of Dijincao Tablets (Euphorbia humifusa Willd.) on T-lymphocytes subsets and cytokines in patients with immune thrombocytopenia (ITP).METHODS Fifty-six patients who were first diagnosed ITP at hematology department of our hospital from Jan.2014 to Dec.2015 were divided into observation group (twenty-eight cases) and control group (twenty-eight cases) by Stratified blocked randomization.The patients in the observation group were given Dijincao Tablets (4.8 g,tid) based on the conventional treatment,while the patients in the control group only accepted conventional treatment according to guidelines.Adverse events were collected during the treatment.Fasting venous blood was obtained from all patients in the morning on the second day of admission and the weekend of the forth week (30th day after admission) to detect observation indexes,and then the comprehensive effects were evaluated.The levels of T-lymphocytes subsets of CD3 +,CD4 +,CD8 + and CD4 +/CD8 + were examined by flow cytometry,and serum cytokine levels of IL-2,IFN-γ,IL-4 and IL-10 were determined by ELISA.RESULTS The total effective rate was 92.9％ in the observation group,which was higher than 82.1％ in the control group.The platelet level in the observation group was significantly higher than that in the control group.Compared with the control group,the levels of CD3 +,CD4 + and CD4 +/CD8 + in the observation group were significantly increased,the levels of IL-2 and IFN-γwere significantly decreased,and the ratio of IFN-γ/IL-4 was significantly decreased.CONCLUSION Dijincao Tablets can correct and regulate the disorder and ratio of T-lymphocyte subsets,and decrease the ratio of IFN-γ/IL-4,then achieve therapeutic effect on patients with immune thrombocytopenia.
ABSTRACT
<p><b>OBJECTIVE</b>To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin's lymphoma.</p><p><b>METHODS</b>Eighty-two cases of non-Hodgkin's lymphoma were divided into 2 groups: gemcitabine+oxaliplation(Gem+Oxa) group (42 cases) and vinorelbine+oxaliplatin(Vin+Oxa) group (40 cases) according to chemotherapy regimens. The clinical efficacy, side effects, progression-free survival situation in 2 groups were compared.</p><p><b>RESULTS</b>There was no significant difference on the clinical effects of 2 groups (P>0.05); The therapeutic efficacy for B cell lymphoma was higher than that for T cell lymphoma(P<0.05); The therapeutic effects for I-II stages was lower than that for III-IV stages(P<0.05); The incidences of platelet decline, nausea and vomit, peripheral nerve symptoms in Gem+Oxa group were lower than those in Vin+Oxa group(P<0.05); There was no significant difference in the median progression free survival(P>0.05).</p><p><b>CONCLUSION</b>The efficacy of GEMOX regimen for refractory non-Hodgkin's lymphoma has been confirmed to be good, it has distinct clinical curative effect, it can prolong the progression-free survival time in patients with B cell lymphoma, specially for III-IV stages. It can be used as the preferred method for the treatment of patients with refractory NHL.</p>